

**From:** Lees, Paul (HHS/OASH) <Paul.Lees@hhs.gov>  
**Sent:** Monday, July 30, 2018 1:40 PM  
**To:** Michael Carome  
**Cc:** Buchanan, Lisa (HHS/OASH); Menikoff, Jerry (HHS/OASH); Kaneshiro, Julie A (HHS/OASH)  
**Subject:** RE: Follow-up complaint letter about two unethical prospective clinical trials that tested ketamine for agitation

Hello,

The Office for Human Research Protections acknowledges the receipt of this email and the attached letter. We are currently reviewing both studies and their impact on the community. Please send us any other information your organization obtains on the matter when it becomes available to you.

Thank-you for your assistance.

Sincerely,

Paul E. Lees, MPH, MS  
Lieutenant Commander, U.S. Public Health Service  
Public Health Analyst

Division of Compliance Oversight  
Office for Human Research Protections  
1101 Wootton Parkway, Suite 200  
The Tower Building  
Rockville, MD 20852